ClinicalTrials.gg
RecruitingNCT07845942Updated Sep 29, 2026

Allogeneic Hematopoietic Cell Transplantation for Refractory Systemic Juvenile Idiopathic Arthritis.

An observational study in Refractory Systemic Juvenile Idiopathic Arthritis, Systemic Juvenile Idiopathic Arthritis and Systemic Juvenile Idiopathic Arthritis Associated Lung Disease, sponsored by Children's Hospital Medical Center, Cincinnati. Recruiting at 1 site in United States. Open to participants aged Up to 35 Years. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by Children's Hospital Medical Center, Cincinnati · Observational

Updated Sep 29, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
20
Ages
Up to 35 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 109 studies in Arthritis, Juvenile with a site in United States — 20 open to participants now, 23 under way, 5 of them phase 3. Arthritis, Juvenile · United States.

Planned enrollment
24th of 24
20 · median 288
Started
2026
with 5 others
Observational
24 of 109
10 open now
Primary completion
2031-07
later than 20 of 21 live
Registered
108th of 109
by date
Lead sponsor
6 of 109
Children's Hospital Medical Center, Cincinnati

Among the 109 studies in Arthritis, Juvenile with a site in United States, this one is the 24th largest by planned enrollment of the 24 observational ones that give a count, is one of 6 that started in 2026, is one of 24 observational ones, reaches primary completion later than 20 of the 21 other live ones, and was the 108th registered.

Arthritis, Juvenile

366 studies on the registry are indexed under Arthritis, Juvenile; 102 are open to participants now.

Browse Arthritis, Juvenile studies →

Open to participants now

20 of the 109 studies in Arthritis, Juvenile with a site in United States are open now. Recruiting first, the newest first:

14 more — sign in →

All 20 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 69 Arthritis, Juvenile studies recruiting now, 13 (19%) set no upper age limit and 50 (72%) stop at 75 or younger; 65 take children under 18; 11 take healthy volunteers.

This study: Up to 35 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 109 studies in Arthritis, Juvenile with a site in United States, or all of them as a file.
02

Study summary

The goal of this study is to collect clinical data and samples and to evaluate the feasibility of allogeneic hematopoietic cell transplantation (HCT) in children and young adults with refractory Systemic Juvenile Idiopathic Arthritis (sJIA), including those with sJIA-associated lung disease (sJIA-LD).

03

Conditions studied

  • Refractory Systemic Juvenile Idiopathic Arthritis
  • Systemic Juvenile Idiopathic Arthritis
  • Systemic Juvenile Idiopathic Arthritis Associated Lung Disease

Browse trials for

04

Who can participate

Ages eligible
Up to 35 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Children and young adults \<35 years of age with longstanding Systemic Juvenile Idiopathic Arthritis diagnosed in childhood will be enrolled if they meet the eligibility criteria below. Patients with Systemic Juvenile Idiopathic Arthritis associated lung disease are included and will be specifically evaluated.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients \<35 years of age are eligible, and participants must meet all the following criteria to be eligible for this study:
  • Diagnosis: Systemic Juvenile Idiopathic Arthritis (sJIA) diagnosed prior to age 16, fulfilling ILAR classification criteria for sJIA or the provisional PRINTO criteria for systemic arthritis. The diagnosis and disease course must be reviewed and confirmed by a pediatric rheumatologist.
  • Disease: sJIA that is refractory to standard therapy, defined as meeting at least one of these conditions despite appropriate treatment:
  • Persistent JIA activity: Ongoing active disease (e.g. uncontrolled arthritis or systemic features such as fever, rash, organ inflammation) or progressive joint damage or liver dysfunction that has not responded to biologic agents (IL-1/IL-6 inhibitors) and conventional therapies, or inability to wean from high-dose (steroid dependence).
  • Recurrent MAS: Two or more episodes of macrophage activation syndrome within a 2-year period, indicating a failure to control the hyperinflammation with medical management. (MAS is defined by clinical and laboratory criteria such as fever, cytopenias, hyperferritinemia, hemophagocytosis, etc., per standard definitions.)
  • sJIA-LD: Presence of lung disease related to sJIA, either symptomatic LD (e.g. chronic cough, tachypnea, hypoxemia) or progressive LD on imaging (worsening interstitial changes), meeting clinical/imaging features such as patchy ground-glass opacities, septal and pleural thickening, or clubbing of digits. sJIA-LD should be confirmed by a pulmonologist/radiologist (e.g. HRCT findings).

Exclusion criteria

Exclusion Criteria:

  • Uncontrolled Infection: Presence of a severe, uncontrolled infection at time of enrollment (e.g. sepsis, pneumonia not responding to therapy).
  • Significant Organ Failure:
  • Cardiac: EF \< 40%
  • Renal: \< 30 ml/hr
  • Active : Concurrent cancer diagnosis or history of malignant disease requiring active treatment.
  • Pregnancy or Lactation: Female patients who are pregnant or breastfeeding. Female participants of must have a negative pregnancy test clinical result at screening (pregnancy testing is done as standard of care for all transplant patients).
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
20 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Overall Survival at 1 year

    Time frame: 1-year post-transplant

Secondary outcomes

  1. sJIA clinical remission

    Proportion achieving clinical remission/ inactive diasease at 1 year

    Time frame: 1-year post-transplant

  2. Corticosteroid and biologic independence

    Time to discontinuation of corticosteroids and biologic therapy following HCT.

    Time frame: Time Frame: 1-year post-transplant

  3. Graft Failure

    Incidence of primary and secondary graft failure following HCT.

    Time frame: 1-year post-transplant

  4. Acute and Chronic Graft-Versus-Host Disease (GVHD)

    Incidence and severity of acute and chronic GVHD following HCT.

    Time frame: 1-year post-transplant

  5. Transplant-Related Mortality

    Incidence of mortality attributable to transplant-related complications.

    Time frame: 1-year post-transplant

  6. Pulmonary Outcomes in Participants With sJIA-LD

    Changes in pulmonary disease following HCT, assessed using pulmonary function testing and physician global assessment of lung disease (PGALD).

    Time frame: 1-year post-transplant

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Jul 2031, 56 months later.

Of 42 observational studies under Arthritis, Juvenile, half reached primary completion within 81 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 186. This study's planned 56 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2026
First posted
Sep 29, 2026
StartEst.
Nov 2026
Primary completionEst.
Jul 2031
CompletionEst.
Jul 2031
Last update
Sep 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Sep 29, 2026
Show all 1 update
  1. Sep 29, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07845942
Responsible party
Sponsor
First posted
Sep 29, 2026
Start date
Nov 2026 (estimated)
Primary completion
Jul 2031 (estimated)
Completion
Jul 2031 (estimated)
Last update
Sep 29, 2026

Study contacts

Sharat Chandra, MD
Contact
Sharat.Chandra@cchmc.org
513-636-5917
Sharat Chandra, MD
principal investigator · Children's Hospital Medical Center, Cincinnati

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion